Overview
The WhiteDove Engine is at the forefront of stem cell research for Type 1 Diabetes (T1D). Our goal is to harness the regenerative potential of pluripotent stem cells to replenish the insulin-producing beta cells lost in T1D. By developing advanced differentiation protocols and cell culture techniques, we aim to create functional beta cells capable of restoring endogenous insulin production and achieving long-term glycemic control.
Research Focus Areas
- Stem cell sourcing and optimization: Identifying the most promising stem cell sources, including embryonic stem cells and induced pluripotent stem cells (iPSCs), and optimizing their expansion and differentiation potential.
- Beta cell differentiation: Developing precise differentiation protocols to guide stem cells through the stages of pancreatic development, ultimately generating mature, glucose-responsive beta cells.
- Cell encapsulation and immune protection: Engineering advanced encapsulation technologies to protect transplanted beta cells from immune rejection while allowing efficient insulin release.
- Preclinical testing and safety assessment: Conducting rigorous in vitro and in vivo studies to evaluate the functionality, safety, and long-term viability of stem cell-derived beta cells.
Collaborative Partnerships
The WhiteDove Engine actively collaborates with leading academic institutions, research organizations, and industry partners to accelerate the translation of stem cell therapies for T1D. Our collaborative efforts leverage complementary expertise, resources, and technologies to drive innovation and bring transformative treatments to patients.
